Brie Carter

Acrow (ASX:ACF) reported $336 million in revenue for the 2026 financial year.

Rhythm Pharmaceuticals (NASDAQ:RYTM) received Japanese marketing authorization for its IMCIVREE therapy, targeting a company-estimated 5,000 to 8,000 obesity patients.

Monte Rosa Therapeutics (NASDAQ:GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 trial evaluating investigational molecular glue degrader MRT-2359 with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer.

NAPCO Security Technologies (NASDAQ:NSSC) reported fiscal Q4 2026 revenue of $55.8 million, up 10% year-over-year, driven by growth in recurring service and equipment revenue.

XPENG (NYSE:XPEV) reported a second-quarter total revenue of RMB19.74 billion (US$2.91 billion) driven by strong vehicle sales.

Robo.ai (NASDAQ:AIIO) reported net revenue of US$55.1 million for the six months ended June 30, 2026.

Phantom will end support for Sui (CRYPTO:SUI) on 24 September, according to an announcement on 24 August.

Acadia Pharmaceuticals (NASDAQ:ACAD) announced that the European Commission approved DAYBU (trofinetide) for Rett syndrome in adults and pediatric patients aged five years and older, making it the first approved Rett syndrome treatment in the European Union.

Pakistan’s Virtual Assets Regulatory Authority has opened its licensing portal for crypto businesses.

Biogen (NASDAQ:BIIB) and Eisai announced that LEQEMBI IQLIK, a once-weekly subcutaneous lecanemab-irmb autoinjector, is now available in the United States for adults with early Alzheimer’s disease.